Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Stimulants01:29

Stimulants

1.4K
Stimulants are substances that enhance neural activity and elevate dopamine levels in the brain, leading to their highly addictive nature. These drugs include cocaine, amphetamines, MDMA, caffeine, and nicotine, each with distinct mechanisms of action and varied health implications.
Cocaine can be administered via snorting, injection, or smoking. It primarily functions by blocking the reuptake of dopamine, resulting in a euphoric high characterized by an intense sensation of happiness and...
1.4K
CNS Stimulants: Cocaine, Amphetamines and Cannabinoids01:24

CNS Stimulants: Cocaine, Amphetamines and Cannabinoids

1.4K
CNS stimulants, such as cocaine, amphetamines, and cannabinoids, have varying structures and mechanisms of action that lead to different therapeutic effects and side effects. Cocaine, with its molecular formula C17H21NO4, is a tropane alkaloid and a tertiary amino compound. It has two chemical forms: the hydrochloride salt and the "freebase." The former is in powder form, while the latter involves removing the hydrochloride salt to create a form that can be smoked. Cocaine exerts its...
1.4K
Substance Use Disorders Affecting Sleep01:24

Substance Use Disorders Affecting Sleep

606
Substance use disorders involve a pattern of using drugs more extensively than intended and continuing use despite harmful consequences. This includes legal substances like alcohol and nicotine, as well as illegal drugs. These disorders often involve both physical and psychological dependence, reflecting compulsive use of substances that significantly alter thoughts, feelings, and behaviors, contributing to a major public health issue.
Understanding the concepts of physical dependence,...
606
Adrenergic Agonists: Indirect-Acting Agents01:25

Adrenergic Agonists: Indirect-Acting Agents

2.8K
Indirect-acting adrenergic agonists potentiate the effects of endogenous catecholamines through different mechanisms without directly binding to adrenoceptors.
One mechanism involves depleting stored catecholamines by displacing them from synaptic vesicles. These agents, known as "displacers," are transported into vesicles at the expense of noradrenaline. Examples include amphetamine and tyramine, which lack a catechol moiety, resulting in prolonged action, improved oral...
2.8K
Adrenergic Agonists: Mixed-Action Agents01:28

Adrenergic Agonists: Mixed-Action Agents

1.7K
Mixed-action adrenergic agonists, like ephedrine and pseudoephedrine, directly and indirectly affect adrenergic receptors. These agents stimulate adrenoceptors and indirectly release stored neurotransmitters, amplifying the adrenergic response.
Ephedrine and pseudoephedrine lack a catecholamine group, making them less susceptible to degradation by metabolic enzymes. They have increased oral bioavailability and lipophilicity, resulting in a longer duration of action. Their response is reduced by...
1.7K
Drugs Acting on Autonomic Ganglia: Stimulants01:23

Drugs Acting on Autonomic Ganglia: Stimulants

2.2K

Ganglionic stimulants activate NM nicotinic receptors in autonomic ganglia, falling into two categories: nicotine mimetics [e.g., lobeline, dimethylpiperazine, tetramethylammonium] and muscarinic receptor agonists [e.g., muscarine, methacholine]. The first category's action is rapid and blocked by nicotinic receptor antagonists, while the second category's action is delayed and blocked by atropine-like agents. Nicotine, an alkaloid, affects the heart rate by stimulating...
2.2K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same journal

Biological and social rhythm differences, daily melatonin secretion and psychiatric symptoms in healthy adults.

International journal of psychiatry in clinical practice·2026
Same journal

Diagnostic utility of pan-immune inflammation value in drug-naïve first-episode psychosis.

International journal of psychiatry in clinical practice·2026
Same journal

Examining neuroretinal alterations in autism spectrum disorder: a systematic review of OCT and OCT-A studies.

International journal of psychiatry in clinical practice·2026
Same journal

Depressive symptoms in patients with schizophrenia spectrum disorders and the impact on treatment motivation and satisfaction.

International journal of psychiatry in clinical practice·2026
Same journal

Predictors of premature treatment termination in an inpatient programme for women with PTSD and/or eating disorders.

International journal of psychiatry in clinical practice·2026
Same journal

Evaluation of haematological parameters in patients with first-episode psychosis: distinctions between bipolar disorder and schizophrenia spectrum disorders.

International journal of psychiatry in clinical practice·2026
See all related articles

Related Experiment Video

Updated: Apr 28, 2026

Caffeine Extraction, Enzymatic Activity and Gene Expression of Caffeine Synthase from Plant Cell Suspensions
09:11

Caffeine Extraction, Enzymatic Activity and Gene Expression of Caffeine Synthase from Plant Cell Suspensions

Published on: October 2, 2018

12.9K

Caffeine: The forgotten variable.

C P Beer

    International Journal of Psychiatry in Clinical Practice
    |June 13, 2014
    PubMed
    Summary
    This summary is machine-generated.

    Individual responses to caffeine vary due to genetics, impacting susceptibility and metabolism. Caffeine can cause toxicity, withdrawal, and interact with psychiatric medications, necessitating consumption inquiries in treatment-resistant cases.

    Keywords:
    Caffeine Depression Panic Anxiety Schizophrenia

    More Related Videos

    Experimental Protocol for Examining Behavioral Response Profiles in Larval Fish: Application to the Neuro-stimulant Caffeine
    08:33

    Experimental Protocol for Examining Behavioral Response Profiles in Larval Fish: Application to the Neuro-stimulant Caffeine

    Published on: July 24, 2018

    14.5K
    Assaying β-amyloid Toxicity using a Transgenic C. elegans Model
    13:59

    Assaying β-amyloid Toxicity using a Transgenic C. elegans Model

    Published on: October 9, 2010

    25.6K

    Related Experiment Videos

    Last Updated: Apr 28, 2026

    Caffeine Extraction, Enzymatic Activity and Gene Expression of Caffeine Synthase from Plant Cell Suspensions
    09:11

    Caffeine Extraction, Enzymatic Activity and Gene Expression of Caffeine Synthase from Plant Cell Suspensions

    Published on: October 2, 2018

    12.9K
    Experimental Protocol for Examining Behavioral Response Profiles in Larval Fish: Application to the Neuro-stimulant Caffeine
    08:33

    Experimental Protocol for Examining Behavioral Response Profiles in Larval Fish: Application to the Neuro-stimulant Caffeine

    Published on: July 24, 2018

    14.5K
    Assaying β-amyloid Toxicity using a Transgenic C. elegans Model
    13:59

    Assaying β-amyloid Toxicity using a Transgenic C. elegans Model

    Published on: October 9, 2010

    25.6K

    Area of Science:

    • Pharmacology
    • Psychiatry
    • Genetics

    Background:

    • Caffeine is widely consumed, but individual responses vary significantly.
    • Genetic factors, including adenosine receptors and metabolism, influence caffeine sensitivity.
    • Caffeine is recognized as a potential drug of abuse with known toxic effects.

    Purpose of the Study:

    • To explore the genetic basis of individual differences in caffeine consumption and susceptibility.
    • To review the clinical implications of caffeine's effects and interactions in psychiatric patients.
    • To highlight the importance of assessing caffeine intake in managing psychiatric conditions.

    Main Methods:

    • Literature review of studies on caffeine pharmacology, genetics, and clinical effects.
    • Analysis of case reports and clinical guidelines concerning caffeine use and psychiatric treatment.
    • Pharmacogenetic review of caffeine metabolism and adenosine receptor interactions.

    Main Results:

    • Individual caffeine metabolism and adenosine receptor variations contribute to differential susceptibility.
    • Caffeine can induce anxiety, insomnia, and exacerbate psychosis; it also affects psychotropic drug metabolism (e.g., clozapine via CYP1A2 inhibition).
    • Caffeine withdrawal symptoms and tolerance are documented, with clinical recognition by DSM and ICD-10.

    Conclusions:

    • Genetic variability significantly impacts caffeine's effects and metabolism.
    • Clinicians should inquire about caffeine consumption in patients with treatment-refractory illnesses or unusual drug sensitivities/tolerances.
    • Understanding caffeine intake is crucial for optimizing psychiatric treatment and avoiding adverse drug interactions.